May 11, 2022
FDA: Class I recall of certain Accula SARS-CoV-2 Tests
Editor's Note
The Food and Drug Administration (FDA) on May 9 identified the recall by Mesa Biotech, Inc, of certain Accula SARS-CoV-2 Tests as Class I, the most serious.
The recall was initiated because certain lots of the PCR test have an increased risk of giving false positive results because of contamination at the manufacturing facility.
Distribution dates were January 19 to February 8, 2022.
Free Daily News
- Quality Improvement: Reduce Specimen Labeling Errors
- Staffing Strategy: Grow Your Middle Management
- Olympus issues voluntary labeling update for bronchoscopes used with laser therapy equipment
- NorthStar Anesthesia scales ASC partnerships in Georgia with transparent, clinician-driven model
- Targeted intraoperative radiation slashes pancreatic cancer recurrence to 5%
- Ambient AI reshapes nursing workflows and boosts patient interaction
- Session: Developing a complex spine and total joint service line program in the ASC
- Session: The importance of having a comprehensive plan to prevent workplace violence in ASCs
- Session: Automate to elevate—Streamlining pre-, postoperative processes for better outcomes in ASCs
- Transparent oversight is key to safe surgical innovation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement